2025
Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022–2023
Hurley L, Kurlandsky K, Breslin K, Stein A, Hambidge S, Shoup J, Reifler L, Daley M, Lewin B, Goddard K, Henninger M, Nelson J, Vazquez-Benitez G, Hanson K, Fuller C, Williams J. Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022–2023. Human Vaccines & Immunotherapeutics 2025, 21: 2467548. PMID: 40179339, PMCID: PMC11980469, DOI: 10.1080/21645515.2025.2467548.Peer-Reviewed Original Research
2024
Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults
Kometani K, Yorimitsu T, Jo N, Yamaguchi E, Kikuchi O, Fukahori M, Sawada T, Tsujimoto Y, Sunami A, Li M, Ito T, Pretemer Y, Gao Y, Hidaka Y, Yamamoto M, Kaku N, Nakagama Y, Kido Y, Grifoni A, Sette A, Nagao M, Morita S, Nakajima T, Muto M, Hamazaki Y. Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults. Frontiers In Immunology 2024, 15: 1455334. PMID: 39717779, PMCID: PMC11663736, DOI: 10.3389/fimmu.2024.1455334.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntibodies, ViralB-LymphocytesCD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesFemaleHumansImmunity, HumoralImmunization, SecondaryImmunoglobulin GImmunologic MemoryMaleMemory B CellsMiddle AgedmRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusYoung AdultConceptsB cell responsesT cell responsesB cellsT cellsBooster vaccinationT cell-mediated cellular immunityCD8<sup>+</sup> T cell responsesCytotoxic CD8<sup>+</sup> T cell responsesReduced PD-1 expressionMemory T cell activationMemory B cell responsesCOVID-19 mRNA booster vaccinationPD-1 expressionCOVID-19 mRNA vaccinesMemory T cellsImpaired humoral immunityImpaired B cellYoung adultsT cell activationMRNA booster vaccinationEnhanced IgG responseSpike-specificCellular immunityMRNA vaccinesAge-associated differences
2023
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Hulme W, Williamson E, Horne E, Green A, McDonald H, Walker A, Curtis H, Morton C, MacKenna B, Croker R, Mehrkar A, Bacon S, Evans D, Inglesby P, Davy S, Bhaskaran K, Schultze A, Rentsch C, Tomlinson L, Douglas I, Evans S, Smeeth L, Palmer T, Goldacre B, Hernán M, Sterne J. Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data. Annals Of Internal Medicine 2023, 176: m21-4269. PMID: 37126810, PMCID: PMC10152408, DOI: 10.7326/m21-4269.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineRandomized trialsObservational studyCOVID-19 vaccinationDuration of protectionBooster vaccinationFirst doseTrial emulationNew virus variantsVaccinated personsEligible personsVaccine rolloutVaccinationTarget trialsVirus variantsTrialsVaccineTime-varying variablesBaselineRobust evidenceSingle trial approachRapid uptakePersonsConfoundersDose
2022
Immunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineCOVID-19COVID-19 VaccinesHumansImmunization, SecondaryProspective StudiesConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDosesBooster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Mai A, Lee A, Tay R, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff R, LaFleur B, Bhattacharya D, Peng S, Tey J, Lee S, Chai L, Soon Y, Sundar R, Lee M. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal Of Cancer 2022, 172: 65-75. PMID: 35753213, PMCID: PMC9163022, DOI: 10.1016/j.ejca.2022.05.029.Peer-Reviewed Original ResearchConceptsIndividual Patient Data Meta-AnalysisPatient data meta-analysisSolid cancersBooster doseNon-respondersData Meta-AnalysisHaematological cancersMeta-analysisAntibody titresBooster dose of COVID-19 vaccineAssociated with increased durationIncreased risk of severe diseaseResponse to booster vaccinationAge of patientsRisk of severe diseaseVaccine non-respondersDose of COVID-19 vaccineSystematic reviewJoanna Briggs Institute Critical Appraisal ChecklistGastrointestinal cancer patientsCOVID-19 vaccine booster doseReduced vaccine immunogenicityVaccine booster doseImproved seroconversionCritical Appraisal Checklist
2021
Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
Croda J, Ranzani O. Booster doses for inactivated COVID-19 vaccines: if, when, and for whom. The Lancet Infectious Diseases 2021, 22: 430-432. PMID: 34890538, PMCID: PMC8651253, DOI: 10.1016/s1473-3099(21)00696-4.Peer-Reviewed Original Research
2018
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules
Moïsi J, Yaro S, Kroman S, Gouem C, Bayane D, Ganama S, Meda B, Nacro B, Njanpop-Lafourcade B, Ouangraoua S, Ouedraogo I, Sakande S, Sawadogo F, Zida S, Ouedraogo J, Gessner B. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 422-432. PMID: 30299491, DOI: 10.1093/jpids/piy075.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntibodies, BacterialBurkina FasoChild, PreschoolFemaleHumansImmunization ScheduleImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInfantMaleOpsonin ProteinsPhagocytosisPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal conjugate vaccineMonths of ageConjugate vaccineStudy armsImmune responseDoses of PCVAge groupsDoses 2 monthsSerum immunoglobulin G concentrationBurden of morbidityStreptococcus pneumoniae infectionStrong primary immune responsesRoutine immunization programPrimary immune responseRobust memory responsesMajority of serotypesYears of ageWeeks of ageImmunoglobulin G concentrationBooster doseReactogenicity dataReactogenicity profileSatisfactory immunogenicityOpsonophagocytic activityPneumoniae infectionSeroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease
Phatak U, Rojas‐Velasquez D, Pashankar DS. Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease. Journal Of Pediatric Gastroenterology And Nutrition 2018, 66: e137-e137. PMID: 29287017, DOI: 10.1097/mpg.0000000000001885.Peer-Reviewed Original Research
2017
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansImmunization, SecondaryInfluenza VaccinesInfluenza, HumanMaleMiddle AgedMultiple MyelomaPilot ProjectsWaldenstrom MacroglobulinemiaConceptsPlasma cell disordersSerologic responseInfluenza vaccinationInfluenza vaccineMultiple myelomaCell disordersInfluenza infectionVaccination strategiesHigh-dose influenza vaccineInactivated trivalent influenza vaccineLaboratory-confirmed influenza infectionBooster vaccination strategiesStandard vaccination strategyTwo-dose seriesLaboratory-confirmed influenzaSeasonal influenza vaccinationTrivalent influenza vaccineSingle-arm trialPlasma cell dyscrasiaDisease response assessmentLogistic regression modelsSeroprotection ratesActive therapyAdverse eventsPartial response
2016
Cost-effectiveness of next-generation vaccines: The case of pertussis
Fitzpatrick MC, Wenzel NS, Scarpino SV, Althouse BM, Atkins KE, Galvani AP, Townsend JP. Cost-effectiveness of next-generation vaccines: The case of pertussis. Vaccine 2016, 34: 3405-3411. PMID: 27087151, DOI: 10.1016/j.vaccine.2016.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChildCost-Benefit AnalysisHumansImmunization, SecondaryInfantModels, TheoreticalPertussis VaccineQuality-Adjusted Life YearsVaccinationWhooping CoughConceptsNext-generation vaccinesDuration of protectionAdult boostersChildhood seriesAge-structured transmission modelVaccination coverage ratesCases of pertussisPublic health challengePerfect efficacyPertussis vaccinationPertussis vaccinePertussis incidenceCurrent vaccinesNew vaccinesPotential vaccinesGreater efficacyVaccineVaccine improvementHealth challengesAverage durationHealth benefitsEfficacyDoseShort durationPertussis
2011
The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results
Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 2011, 29: 6107-6112. PMID: 21736912, PMCID: PMC3164284, DOI: 10.1016/j.vaccine.2011.06.076.Peer-Reviewed Original ResearchConceptsBooster vaccinationHIV prevalencePopulation coverage levelsRV144 trialHIV vaccineCondom useContinuous vaccinationHIV vaccine regimenPopulation HIV prevalenceDuration of protectionCoverage levelsRV144 vaccineVaccine regimenHIV infectionHeterosexual transmissionModest efficacyVaccine efficacyUnvaccinated populationVaccination strategiesPartial efficacyEfficacy vaccineLower riskVaccinationBooster strategyVaccineTLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia)
Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D. TLR1/2 Activation during Heterologous Prime-Boost Vaccination (DNA-MVA) Enhances CD8+ T Cell Responses Providing Protection against Leishmania (Viannia). PLOS Neglected Tropical Diseases 2011, 5: e1204. PMID: 21695103, PMCID: PMC3114751, DOI: 10.1371/journal.pntd.0001204.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDisease Models, AnimalFemaleGenetic VectorsImmunization, SecondaryInterferon-gammaInterleukin-10Interleukin-13LeishmaniaLeishmaniasisLeishmaniasis VaccinesMiceMice, Inbred BALB CPeroxidasesProtozoan ProteinsRodent DiseasesToll-Like Receptor 1Toll-Like Receptor 2VaccinationVaccines, DNAVaccines, SyntheticVaccinia virusViral VaccinesConceptsPrime-boost vaccinationHeterologous prime-boost vaccinationCD8 T cellsT cell responsesT cellsTLR1/2 activationIL-10Vaccination modalityIL-13Immune responseAntigen-specific CD8 cellsCD8 T cell responsesCell responsesL. panamensis infectionsSpecific CD8 cellsTLR1/2 agonist Pam3CSK4IL-10 responsesVaccine-induced protectionCD4 T cellsMurine immune responseIL-13 responsesLeishmania speciesInfection/diseaseVaccinia virus AnkaraInnate immune response
2006
γδ T Cells Facilitate Adaptive Immunity against West Nile Virus Infection in Mice
Wang T, Gao Y, Scully E, Davis CT, Anderson JF, Welte T, Ledizet M, Koski R, Madri JA, Barrett A, Yin Z, Craft J, Fikrig E. γδ T Cells Facilitate Adaptive Immunity against West Nile Virus Infection in Mice. The Journal Of Immunology 2006, 177: 1825-1832. PMID: 16849493, DOI: 10.4049/jimmunol.177.3.1825.Peer-Reviewed Original ResearchMeSH KeywordsAdoptive TransferAnimalsCD8-Positive T-LymphocytesGenetic Predisposition to DiseaseImmunity, CellularImmunity, InnateImmunization, SecondaryImmunoglobulin GImmunoglobulin MImmunologic MemoryLymphocyte DepletionMiceMice, Inbred C57BLMice, KnockoutReceptors, Antigen, T-Cell, gamma-deltaRecurrenceT-Lymphocyte SubsetsWest Nile FeverWest Nile virusConceptsGammadelta T cellsWild-type miceT cellsWN virus infectionPrimary infectionVirus infectionWN virusNaive miceSecondary challengeImmune responseAdaptive immunityCD8 memory T cellsWest Nile virus infectionMemory T cellsProtective immune responseAdaptive immune responsesAdoptive transferWest Nile virusAb responsesLethal infectionViral challengeFatal meningoencephalitisSecondary infectionInfectionMice
2004
Rapid Development of T Cell Memory
Wong P, Lara-Tejero M, Ploss A, Leiner I, Pamer EG. Rapid Development of T Cell Memory. The Journal Of Immunology 2004, 172: 7239-7245. PMID: 15187098, DOI: 10.4049/jimmunol.172.12.7239.Peer-Reviewed Original ResearchConceptsMemory T cellsT cell populationsPrimary immune responseT cellsPrimary immunizationImmune responseMemory CD8 T cell responsesAg-specific CD8 T cellsCD8 T cell responsesEarly memory T cellsCD8 T cell populationsEffector T cell populationsPrime-boost immunizationPrime-boost vaccinationCD8 T cellsPrime-boost strategyT cell memoryT cell responsesCell populationsEarly time pointsProtective immunityAg doseCell memoryCell responsesImmunization
2001
An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants
Rose N, Marx P, Luckay A, Nixon D, Moretto W, Donahoe S, Montefiori D, Roberts A, Buonocore L, Rose J. An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants. Cell 2001, 106: 539-549. PMID: 11551502, DOI: 10.1016/s0092-8674(01)00482-2.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS VaccinesAnimalsCD4 Lymphocyte CountCD4-Positive T-LymphocytesEnzyme-Linked Immunosorbent AssayGene Products, envGene Products, gagHIVHIV AntibodiesHumansImmunization, SecondaryMacaca mulattaMiceNeutralization TestsPilot ProjectsRecombinant Fusion ProteinsSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian immunodeficiency virusT-Lymphocytes, CytotoxicTime FactorsVaccines, AttenuatedVaccines, SyntheticVesicular stomatitis Indiana virusViral LoadVirus Shedding
2000
Varicella vaccine revisited
LaRussa P, Steinberg S, Shapiro E, Vazquez M, Gershon A. Varicella vaccine revisited. Nature Medicine 2000, 6: 1299-1299. PMID: 11100089, DOI: 10.1038/82070.Commentaries, Editorials and LettersAdultChickenpoxChickenpox VaccineChildExanthemaHerpes ZosterHerpesvirus 3, HumanHumansImmunization, SecondaryGlycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1
Rose N, Roberts A, Buonocore L, Rose J. Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1. Journal Of Virology 2000, 74: 10903-10910. PMID: 11069984, PMCID: PMC113169, DOI: 10.1128/jvi.74.23.10903-10910.2000.Peer-Reviewed Original ResearchConceptsRecombinant VSV vectorVesicular stomatitis virusNeutralizing antibodiesPrimary isolatesVSV vectorsHigh-titer neutralizing antibodiesHuman immunodeficiency virus type 1Human immunodeficiency virus envelope proteinImmunodeficiency virus type 1HIV primary isolatesCross-neutralizing antibodiesRecombinant vesicular stomatitis virusVirus type 1Effective vaccine vectorAntibody titersWild-type vesicular stomatitis virusHIV envelopeForeign antigensImmune responseVirus envelope proteinVSV Indiana serotypeVaccine vectorType 1AntibodiesG protein gene
1991
Protection of Mice from Lyme Borreliosis by Oral Vaccination with Escherichia coli Expressing OspA
Fikrig E, Barthold S, Kantor F, Flavell R. Protection of Mice from Lyme Borreliosis by Oral Vaccination with Escherichia coli Expressing OspA. The Journal Of Infectious Diseases 1991, 164: 1224-1227. PMID: 1955724, DOI: 10.1093/infdis/164.6.1224.Peer-Reviewed Original ResearchConceptsOral vaccinationRecombinant OspARecombinant outer surface protein AProtection of miceSerum IgG antibodiesSurface protein ALast boostOuter surface protein AControl miceChallenge infectionIgG antibodiesIntraperitoneal injectionLive Escherichia coliOral preparationsC3H/Day 10Lyme borreliosisVaccinationMiceInfectionBorrelia burgdorferiOspAAntibodiesProtein AGavage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply